Skip to content

Lexicon Pharmaceuticals

US · LXRX #3430 by market cap
1.73 -0.04 -1.99%
Live - 5344 symbols - heartbeat 296s ago · 2026-10-08 09:59
Pre-market 1.75 -0.57%
After-hours 1.76 0.00%
Overnight 1.78 +1.14%
Market cap
767.55M
P/B
4.40
EPS
-0.14
Reader sentiment Are you bullish or bearish on LXRX?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Piper Sandler Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6
    Market Newswire · 2026/8/7
  • Rating change
    Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Raises Target Price to $3.1
    Market Newswire · 2026/5/11
  • Rating change
    Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Cuts Target Price to $1.2
    Market Newswire · 2024/11/28
  • Rating change
    Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $1.9
    Market Newswire · 2025/11/7
  • Rating change
    H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Raises Target Price to $6
    Market Newswire · 2026/3/6
  • Rating change
    Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), ICU Medical (ICUI) and Lexicon Pharmaceuticals (LXRX)
    TipRanks · 2024/11/13
  • Rating change
    Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Raises Target Price to $2.3
    Market Newswire · 2026/3/10
  • Cantor Fitzgerald Initiates Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Announces Target Price $8
    Market Newswire · 2026/9/28
  • Earnings Flash (LXRX) Lexicon Pharmaceuticals Posts Q2 Loss $0.07 a Share, Vs. FactSet Est of $0.05 Loss
    MT Newswires · 2026/8/6
  • Rating change
    Piper Sandler Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Cuts Target Price to $6
    Market Newswire · 2025/5/15
  • Rating change
    Leerink Partners Maintains Lexicon Pharmaceuticals(LXRX.US) With Hold Rating, Maintains Target Price $1
    Market Newswire · 2025/3/11
  • H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6
    Market Newswire · 2026/8/24
  • Rating change
    Piper Sandler Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $10
    Market Newswire · 2024/11/13
  • Rating change
    Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Raises Target Price to $1.9
    Market Newswire · 2025/8/7
  • Rating change
    Needham Maintains Lexicon Pharmaceuticals(LXRX.US) With Hold Rating
    Market Newswire · 2025/3/7
  • Rating change
    H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Cuts Target Price to $6
    Market Newswire · 2024/11/1
  • Rating change
    Analysts Offer Insights on Healthcare Companies: ProQR (PRQR), Lexicon Pharmaceuticals (LXRX) and Carlsmed, Inc. (CARL)
    TipRanks · 2026/4/15
  • Rating change
    Leerink Partners Downgrades Lexicon Pharmaceuticals(LXRX.US) to Hold Rating, Announces Target Price $1
    Market Newswire · 2025/3/5
  • Rating change
    H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $4
    Market Newswire · 2026/1/22
  • Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $3.1
    Market Newswire · 2026/9/11

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 09:59:25 · For reference only, not investment advice and not tailored to your situation.